调强放射治疗同步多西他赛化疗治疗局部晚期老年非小细胞肺癌的临床观察  

Clinical efficacy of intensity modulated radiation therapy combined with docetaxl chemotherapy for elderly locally advanced non-small cell lung cancer

作　　者：彭雷[1] 卢鑫[1] 朱兆峰[1] 苏培英[1] 

机构地区：[1]山东省泰安市肿瘤防治院,泰安271000

出　　处：《中国肿瘤临床与康复》2013年第12期1364-1367,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨调强放射治疗同步多西他赛化疗治疗老年局部晚期非小细胞肺癌的疗效、不良反应及耐受性。方法 35例65岁以上的老年非小细胞肺癌患者(NSCLC)采用调强放射治疗(IMRT),95%计划靶体积(PTV)60Gy,每次2Gy分30次,放射治疗同时每周给予多西他赛35mg/m2,共4～6周。结果总有效率为80.0%(28/35),1年生存率为65.7%,中位生存时间为15.2个月,不良反应较轻,所有患者均能耐受治疗。结论调强放射治疗同步多西他赛化疗是老年局部晚期非小细胞肺癌患者的一种安全有效的治疗手段,能显著改善患者的生存质量,提高生存率,不良反应较轻。Objective To evaluate the effect and adverse reaction of intensity modulated radiation therapy（ IMRT） combined with Docetaxl chemotherapy for elderly advanced non small cell lung cancer（ NSCLC）. Methods 35 elderly NSCLC patients were received IMRT with the total dose of 60Gy/2Gy/ 30f,and concurrent Docetaxl,35mg / m2,administered each radiotherapy week,totally 4-6 weeks. Results Of 35 patients,the overall response rate was 80. 0%（ 28 /35）,the one-year survival rate was 65. 7%,the media duration of survival was 15. 2 months. The adverse reaction was light,and all patients were accepted therapy completely. Conclusions The IMRT combined with Docetaxl was a safe and effective treatment measure in elderly patients with advanced NSCLC,and could improve the quality of life and the survival rate significantly with light adverse reaction.

关 键 词：癌 非小细胞肺 调强放射治疗 多西他赛 同步放化疗 

分 类 号：R734.2[医药卫生—肿瘤]